

PRESCRIBING INFORMATION
INCLUDING PATIENT MEDICATION INFORMATION

^N**COPHYLAC**[®]

Normethadone HCl and p-Hydroxyephedrine HCl Drops

Drops, Normethadone HCl 10 mg/mL (1%) and p-Hydroxyephedrine 20 mg/mL (2%)

Antitussive

Valeant Canada LP
2150 St-Elzear Blvd. West
Laval, Quebec
H7L 4A8

Date of Preparation:
10-14-2014

Date of Revision:
May 30, 2018

Submission Control No: 211403

TABLE OF CONTENTS

PART I: HEALTH PROFESSIONAL INFORMATION.....3
 SUMMARY PRODUCT INFORMATION.....3
 INDICATIONS AND CLINICAL USE.....3
 CONTRAINDICATIONS3
 WARNINGS AND PRECAUTIONS.....4
 ADVERSE REACTIONS.....9
 DRUG INTERACTIONS10
 DOSAGE AND ADMINISTRATION10
 OVERDOSAGE11
 STORAGE AND STABILITY.....11
 DOSAGE FORMS, COMPOSITION AND PACKAGING12

PART II: SCIENTIFIC INFORMATION13
 PHARMACEUTICAL INFORMATION.....13

PART III: CONSUMER MEDICATION INFORMATION.....14

^NCOPHYLAC[®]

Normethadone Hydrochloride and p-Hydroxyephedrine Hydrochloride Drops

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Nonmedicinal Ingredients
Oral	Drops of normethadone HCl 10 mg/mL (1%) and p-hydroxyephedrine HCl 20 mg/mL (2%)	Citric acid anhydrous, glycerine, lemon oil, methylparaben, and purified water.

INDICATIONS AND CLINICAL USE

Adults and Children 6 years and older

COPHYLAC[®] is indicated for the treatment of cough associated with inflamed mucosa, which does not respond to products of lesser potency.

Geriatrics (> 65 years of age)

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, concomitant disease or other drug therapy.

Pediatrics (<6 years of age)

The safety and efficacy of COPHYLAC[®] has not been studied in the pediatric population. Therefore the use of COPHYLAC[®] is not recommended in patients under 6 years of age.

CONTRAINDICATIONS

- Patients who are hypersensitive to the active substances normethadone hydrochloride (HCl) and p-hydroxyephedrine hydrochloride (HCl) or other opioid analgesics or to any ingredient in the formulation. For a complete listing, see the **DOSAGE FORMS, COMPOSITION AND PACKAGING** section of the Product Monograph.
- In patients with known or suspected mechanical gastrointestinal obstruction (e.g., bowel obstruction or strictures) or any diseases/conditions that affect bowel transit (e.g., ileus of any type).
- Patients with suspected surgical abdomen (e.g., acute appendicitis or pancreatitis).

- Patients with acute or severe bronchial asthma, chronic obstructive airway, or status asthmaticus.
- Patients with acute respiratory depression, elevated carbon dioxide levels in the blood and cor pulmonale.
- Patients with acute alcoholism, delirium tremens, and convulsive disorders.
- Patients with severe CNS depression, increased cerebrospinal or intracranial pressure, and head injury.
- Patients taking monoamine oxidase (MAO) inhibitors (or within 14 days of such therapy).
- Women who are breast-feeding, and during pregnancy, or during labour and delivery (see **SERIOUS WARNINGS AND PRECAUTIONS**, and **WARNINGS AND PRECAUTIONS**).

WARNINGS AND PRECAUTIONS

SERIOUS WARNINGS AND PRECAUTIONS

Limitations of Use

Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the risks of overdose and death with immediate release opioid formulations, COPHYLAC[®] (normethadone) should only be used in patients for whom alternative non-opioid treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide appropriate cough management (see **DOSAGE AND ADMINISTRATION**).

Addiction, Abuse, and Misuse

COPHYLAC[®] poses risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Each patient's risk should be assessed prior to prescribing COPHYLAC[®] and all patients should be monitored regularly for the development of these behaviours or conditions (see **WARNINGS AND PRECAUTIONS, Abuse and Misuse**). COPHYLAC[®] should be stored securely to avoid theft or misuse.

Life-threatening Respiratory Depression: OVERDOSE

Serious, life-threatening, or fatal respiratory depression may occur with use of COPHYLAC[®]. Infants exposed in-utero or through breast milk are at risk of life-threatening respiratory depression upon delivery or when nursed. Patients should be monitored for respiratory depression, especially during initiation of COPHYLAC[®] or following a dose increase. Further, instruct patients of the hazards related to taking opioids, including fatal overdose.

Accidental Exposure

Accidental exposure to COPHYLAC[®], especially by children, can result in a fatal overdose of normethadone (see **DOSAGE AND ADMINISTRATION, Disposal, for**

instructions on proper disposal).

Neonatal Opioid Withdrawal Syndrome

Prolonged maternal use of COPHYLAC[®] during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening (see WARNINGS AND PRECAUTIONS, Neonatal Opioid Withdrawal Syndrome (NOWS)).

Interaction with Alcohol

The co-ingestion of alcohol with COPHYLAC[®] should be avoided as it may result in dangerous additive effects, causing serious injury or death (see WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS).

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death (see WARNINGS AND PRECAUTIONS). Avoid use of opioid cough medications in patients taking benzodiazepines, other CNS depressants, or alcohol.

- Reserve concomitant prescribing of COPHYLAC[®] and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.
- Limit dosages and durations to the minimum required.
- Follow patients for signs and symptoms of respiratory depression and sedation.

General

Before prescribing medication to suppress or modify cough, it is important to ascertain that the underlying cause of the cough is identified, that modification of the cough does not increase the risk of clinical or physiological complications, and that appropriate therapy for the primary disease is provided.

Accidental ingestion, especially by children can result in a fatal overdose of normethadone HCl and p-hydroxyephedrine HCl drops (see DOSAGE AND ADMINISTRATION, disposal, for instructions on proper disposal).

Patients should be instructed not to give COPHYLAC[®] to anyone other than the patient for whom it was prescribed, as such inappropriate use may have severe medical consequences, including death. COPHYLAC[®] should be stored securely to avoid theft or misuse.

Abuse and Misuse

Like all opioids, COPHYLAC[®] is a potential drug of abuse and misuse, which can lead to overdose and death. Therefore, COPHYLAC[®] should be prescribed and handled with caution.

Patients should be assessed for their clinical risks for opioid abuse or addiction prior to being prescribed opioids. All patients receiving opioids should be routinely monitored for signs of misuse and abuse.

Use in Drug and Alcohol Addiction

COPHYLAC[®] is an opioid with no approved use in the management of addictive disorders. Its proper usage in individuals with drug or alcohol dependence, either active or in remission is for the management of cough requiring opioids. Patients with a history of addiction to drugs or alcohol may be at higher risk of becoming addicted to COPHYLAC[®]; extreme caution and awareness are warranted to mitigate the risk.

Cardiovascular

Normethadone HCl and p-hydroxyephedrine HCl drops administration may result in hypotension and dizziness.

Dependence/Tolerance

As with other opioids, tolerance and physical dependence may develop upon repeated administration of COPHYLAC[®] and there is a potential for development of psychological dependence.

Physical dependence and tolerance reflect the neuroadaptation of the opioid receptors to chronic exposure to an opioid, and are separate and distinct from abuse and addiction. Tolerance, as well as physical dependence, may develop upon repeated administration of opioids, and are not by themselves evidence of an addictive disorder or abuse.

Patients on prolonged therapy could experience withdrawal symptoms following abrupt discontinuation of therapy or upon administration of an opioid antagonist. Some of the symptoms that may be associated with abrupt withdrawal of an opioid include body aches, diarrhea, gooseflesh, loss of appetite, nausea, nervousness or restlessness, anxiety, runny nose, sneezing, tremors or shivering, stomach cramps, tachycardia, trouble with sleeping, unusual increase in sweating, palpitations, unexplained fever, weakness and yawning (see **ADVERSE REACTIONS, DOSAGE AND ADMINISTRATION, Adjustment or Reduction of Dosage**).

Endocrine

Adrenal Insufficiency

Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency.

Gastrointestinal Effects

Normethadone HCl and p-hydroxyephedrine HCl drops and other morphine-like opioids have been shown to decrease bowel motility. Normethadone HCl and p-hydroxyephedrine HCl drops may obscure the diagnosis or clinical course of patients with acute abdominal conditions.

Patients with chronic constipation should be given COPHYLAC[®] only after weighing the potential therapeutic benefit against the hazards involved.

Neonatal Opioid Withdrawal Syndrome (NOWS)

Use of COPHYLAC[®] is contraindicated in pregnant women (see **CONTRAINDICATIONS**).

Prolonged maternal use of opioids during pregnancy can result in withdrawal signs in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening.

Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn.

Neurologic

Interactions with Central Nervous System Depressants (including benzodiazepines and alcohol): Concomitant use of opioids, including COPHYLAC[®] with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma and death. Because of these risks, avoid use of opioid cough medications in patients taking benzodiazepines, other CNS depressants, or alcohol (see **Drug Interactions**).

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. Because of similar pharmacologic properties, it is reasonable to expect similar risk with concomitant use of opioid cough medications and benzodiazepines, other CNS depressants, or alcohol.

Advise both patients and caregivers about the risks of respiratory depression and sedation if COPHYLAC[®] is used with benzodiazepines, alcohol, or other CNS depressants.

Head Injury: The respiratory depressant effects of normethadone HCl and p-hydroxyephedrine HCl drops, and the capacity to elevate cerebrospinal fluid pressure, may be greatly increased in the presence of an already elevated intracranial pressure produced by trauma. Also, normethadone HCl and p-hydroxyephedrine HCl drops may produce confusion, miosis, vomiting and other side effects which obscure the clinical course of patients with head injury. In such patients, normethadone HCl and p-hydroxyephedrine HCl drops must be used with extreme caution and only if it is judged essential (see **CONTRAINDICATIONS**).

Serotonin syndrome: COPHYLAC[®] could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs (e.g. anti-depressants, migraine medications). Treatment with the serotonergic drug should be discontinued if such events (characterized by clusters of symptoms such as hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes including confusion, irritability, extreme agitation progressing to delirium and coma) occur and supportive symptomatic treatment should be initiated. COPHYLAC[®] should not be used in combination with MAO inhibitors or serotonin-precursors (such as L-tryptophan, oxitriptan) and should be used with caution in combination with other serotonergic drugs (triptans, certain tricyclic antidepressants, lithium, tramadol, St. John's Wort) due to the risk of serotonergic syndrome (see **DRUG INTERACTIONS**).

COPHYLAC[®] should not be consumed with alcohol as it may increase the chance of experiencing dangerous side effects, including death (see **CONTRAINDICATIONS** and **DRUG INTERACTIONS, Drug-Lifestyle Interactions**).

Psychomotor Impairment

COPHYLAC[®] may impair the mental and/or physical abilities needed for certain potentially hazardous activities such as driving a car or operating machinery. Patients should be cautioned accordingly. Patients should also be cautioned about the combined effects of normethadone HCl and p-hydroxyephedrine HCl drops with other CNS depressants, including other opioids, phenothiazine, sedative/hypnotics and alcohol.

Respiratory

Normethadone HCl and p-hydroxyephedrine HCl drops, including COPHYLAC[®] is not recommended for use in any patient in whom respiratory function might be compromised including neuromuscular disorders, severe cardiac or respiratory conditions, lung infections, multiple trauma or extensive surgical procedures.

Life-threatening respiratory depression is more likely to occur in the elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients.

In young children the respiratory centre is especially susceptible to the depressant action of narcotic cough suppressants. Benefit to risk ratio should be carefully considered especially in children with respiratory embarrassment, e.g. croup. Estimation of dosage relative to the child's age and weight is of great importance.

Use in Patients with Chronic Pulmonary Disease: Monitor patients with significant chronic obstructive pulmonary disease or cor pulmonale, and patients having a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression for respiratory depression, particularly when initiating therapy and titrating with COPHYLAC[®], as in these patients, even usual therapeutic doses of COPHYLAC[®] may decrease respiratory drive to the point of apnea. The use of COPHYLAC[®] is contraindicated in patients with acute or severe bronchial asthma, chronic obstructive airway, or status asthmaticus (see **CONTRAINDICATIONS**).

Sexual Function/Reproduction

Long-term use of opioids may be associated with decreased sex hormone levels and symptoms such as low libido, erectile dysfunction, or infertility (see **ADVERSE REACTIONS, Post-Marketing Experience**).

Special Populations

Special Risk Groups: Normethadone HCl and p-hydroxyephedrine HCl drops should be administered with caution to patients with a history of alcohol and drug abuse and in a reduced dosage to debilitated patients, and in patients with severely impaired pulmonary function, Addison's disease, hypothyroidism, myxedema, toxic psychosis, prostatic hypertrophy or urethral stricture.

Pregnant Women: Studies in humans have not been conducted. COPHYLAC[®] crosses the placental barrier and is contraindicated in pregnant women.

Prolonged maternal use of opioids during pregnancy can result in withdrawal signs in the neonate. Neonatal opioid withdrawal syndrome (NOWS), unlike opioid withdrawal syndrome in adults, may be life-threatening (see **WARNINGS AND PRECAUTIONS, Neonatal Opioid Withdrawal Syndrome, ADVERSE REACTIONS, Post-marketing experience**).

Pregnant women using opioids should not discontinue their medication abruptly as this can cause pregnancy complication such as miscarriage or still-birth. Tapering should be slow and under medical supervision to avoid serious adverse events to the fetus.

Labour, Delivery and Nursing Women: Since opioids can cross the placental barrier and are excreted in breast milk, COPHYLAC[®] is contraindicated in nursing women and during labour and delivery. Life-threatening respiratory depression can occur in the infant if opioids are administered during labour. Naloxone, a drug that counters the effects of opiates, should be readily available if COPHYLAC[®] is used in this population.

Pediatrics (<6 years of age): The use of COPHYLAC[®] is not recommended in patients under 6 years of age.

Geriatrics (> 65 years of age): In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range and titrate slowly, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see **DOSAGE AND ADMINISTRATION**).

ADVERSE REACTIONS

Adverse Drug Reaction Overview

The adverse effects of COPHYLAC[®] may include: Drowsiness, insomnia, dizziness, fainting, nausea, vomiting, or a poor appetite, dry mouth, headache, problems with vision, weakness, uncoordinated muscle movement, itching, sweating, constipation.

Post-Marketing Experience

Androgen deficiency: Chronic use of opioids may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the clinical syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted to date. Patients presenting with symptoms of androgen deficiency should undergo laboratory evaluation.

DRUG INTERACTIONS

Interaction with Central Nervous System (CNS) Depressants:

Interaction with Benzodiazepines and Other Central Nervous System (CNS) Depressants (including alcohol): Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants (e.g. other opioids, sedatives/hypnotics, antidepressants, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, phenothiazines, neuroleptics, antihistamines, antiemetics, and alcohol) and beta-blockers, increases the risk of respiratory depression, profound sedation, coma, and death and should be avoided (see **WARNINGS AND PRECAUTIONS, Neurologic, Interactions with Central Nervous System Depressants (including benzodiazepines and alcohol) and Psychomotor Impairment**). COPHYLAC[®] should not be consumed with alcohol as it may increase the chance of experiencing dangerous side effects.

Drug-Lifestyle Interactions

The concomitant use of alcohol should be avoided (see **WARNINGS AND PRECAUTIONS, General**).

DOSAGE AND ADMINISTRATION

All doses of opioids carry an inherent risk of fatal or non-fatal adverse events. This risk is increased with higher doses. The maximum recommended daily dose of COPHYLAC[®] is 30 drops for adults and children over 14 years, and 10-20 drops for children between 6 and 14 years. Each patient should be assessed for their risk prior to prescribing COPHYLAC[®], as the likelihood of experiencing serious adverse events can depend upon the type of opioid and duration of treatment, as well as the patient's own level of tolerance. In addition, the coughing should be assessed routinely to confirm the most appropriate dose and the need for further use of COPHYLAC[®].

Dosing Considerations

COPHYLAC[®] may be taken plain with sugar or in any beverage, preferably after breakfast and at bedtime. Drops are dispensed by inverting the drop dispensing bottle.

Recommended Dose and Dosage Adjustment

Adults and Children over 14 years: The recommended dosage is 15 drops twice daily

Children 6 - 14 years of age: The recommended dosage is 5 to 10 drops twice daily.

Geriatrics: Respiratory depression has occurred in the elderly following administration of large initial doses of opioids to patients who were not opioid-tolerant or when opioids were co-administered with other agents that can depress respiration. COPHYLAC[®] should be initiated at a low dose and slowly titrated to effect (see **WARNINGS AND PRECAUTIONS**).

Adjustment or Reduction of Dosage: Physical dependence with or without psychological dependence tends to occur with chronic administration of opioids, including COPHYLAC[®]. Withdrawal (abstinence) symptoms may occur following abrupt discontinuation of therapy. These symptoms may include body aches, diarrhea, gooseflesh, loss of appetite, nausea, nervousness or restlessness, runny nose, sneezing, tremors or shivering, stomach cramps, tachycardia, trouble with sleeping, unusual increase in sweating, palpitations, unexplained fever, weakness and yawning.

Missed Dose

If the patient forgets to take one or more doses, they should take their next dose at the next scheduled time and in the normal amount.

Disposal

COPHYLAC[®] should be kept in a safe place, out of the sight and reach of children before, during and after use. COPHYLAC[®] should not be used in front of children, since they may copy these actions.

COPHYLAC[®] should never be disposed of in household trash. Disposal via a pharmacy take back program is recommended. Unused or expired COPHYLAC[®] should be properly disposed of as soon as it is no longer needed to prevent accidental exposure to others, including children or pets. If temporary storage is required before disposal, a sealed child-proof container, such as a biohazard waste container or lockable medication box could be obtained from a pharmacy.

OVERDOSAGE

For management of a suspected drug overdose, contact your regional Poison Control Centre.

Symptoms: An overdose of 4 mL taken within 4 to 5 hours has produced transient nausea, cold sweat, and tachycardia in one reported case. Should 33% or more of one bottle be ingested, paralysis of the respiratory centre may result.

Treatment: Overdoses cases must be treated with naloxone HCl.

STORAGE AND STABILITY

COPHYLAC[®] bottles should be stored between 15°C and 30°C.

DOSAGE FORMS, COMPOSITION AND PACKAGING

COPHYLAC[®] (normethadone HCl and p-hydroxyephedrine HCl drops) is available as sugar free solution for oral administration.

Composition:

Each mL of COPHYLAC[®] sugar free solution contains normethadone HCl 10 mg (1%) and p-hydroxyephedrine HCl 20 mg (2%).

COPHYLAC[®] contains the following non-medicinal ingredients: citric acid anhydrous, glycerine, lemon oil, methylparaben and purified water. Energy: 3.3 kJ (0.8 kcal).

Packaging:

COPHYLAC[®] is dispensed in bottles of 15 mL.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name:


Normethadone Hydrochloride

Chemical name:

6-dimethylamino-4,4-diphenyl-hexan-3-one

Molecular formula and molecular mass:

$C_{20}H_{25}NO \cdot HCl$, 331.88 g/mol

Structural formula:**Proper name:**


p-Hydroxyephedrine Hydrochloride

Chemical name:

4-[1-Hydroxy-2-(methylamino)propyl]phenol hydrochloride

Molecular formula and molecular mass:

$C_{10}H_{15}NO_2 \cdot HCl$, 217.69 g/mol

Structural formula:

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE
PATIENT MEDICATION INFORMATION
COPHYLAC[®]

Normethadone Hydrochloride and p-Hydroxyephedrine Hydrochloride Drops

Read this carefully before you start taking COPHYLAC[®] and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about COPHYLAC[®].

Serious Warnings and Precautions

- **Even if you take COPHYLAC[®] as prescribed you are at a risk for opioid addiction, abuse and misuse. This can lead to overdose and death.**
- **You may get life-threatening breathing problems while taking COPHYLAC[®]. This is less likely to happen if you take it as prescribed by your doctor. Babies are at risk of life-threatening breathing problems if their mothers take opioids while pregnant or nursing.**
- **You should never give anyone your COPHYLAC[®]. If a person has not been prescribed COPHYLAC[®], they could die from taking it. This is especially true for children.**
- **If you took COPHYLAC[®] while you were pregnant, whether for short or long periods of time or in small or large doses, your baby can suffer life-threatening withdrawal symptoms after birth. This can occur in the days after birth and for up to 4 weeks after delivery. If your baby has any of the following symptoms:**
 - **has changes in their breathing (such as weak, difficult or fast breathing)**
 - **is unusually difficult to comfort**
 - **has tremors (shakiness)**
 - **has increased stools, sneezing, yawning, vomiting, or fever****Seek immediate medical help for your baby.**
- **Taking COPHYLAC[®] with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.**

What is COPHYLAC[®] used for?

COPHYLAC[®] is used for the temporary relief of cough associated with inflamed mucosa, which does not respond to products of lesser potency.

How does COPHYLAC[®] work?

Normethadone hydrochloride (HCl) and p-hydroxyephedrine hydrochloride (HCl) drops act on the brain to suppress cough.

What are the ingredients in COPHYLAC[®]?

Medicinal ingredients: Normethadone HCl and p-hydroxyephedrine HCl.

Non-medicinal ingredients: Citric acid anhydrous, glycerine, lemon oil, methylparaben and purified water.

COPHYLAC[®] comes in the following dosage forms:

Sugar free solution (drops) containing 1% normethadone HCl and 2% p-hydroxyephedrine HCl.

Do not use COPHYLAC[®] if:

- Your doctor did not prescribe it for you
- You are allergic to normethadone HCl or p-hydroxyephedrine HCl or to any of the other ingredients in COPHYLAC[®]
- You have severe asthma, trouble breathing, or other breathing problems
- You have bowel blockage or narrowing of the stomach or intestines
- You have a head injury
- You are at risk for having seizures
- You have a brain tumor
- You suffer from alcoholism
- You are taking or have taken within the past 2 weeks a Monoamine Oxidase inhibitor (MAOi) (such as phenelzine sulphate, tranylcypromine sulphate, moclobemide or selegiline)
- You are going to have, or recently had, a planned surgery
- You are breastfeeding, pregnant or planning to become pregnant or you are in labour

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take COPHYLAC[®]. Talk about any health conditions or problems you may have, including if you:

- have a history of illicit or prescription drug or alcohol abuse
- have severe kidney or lung disease
- have low blood pressure
- have past or current depression
- suffer from chronic or severe constipation
- have problems with your thyroid, adrenal or prostate gland
- have, or had in the past hallucinations or other severe mental problems
- suffer from migraines
- are planning to become pregnant

Other warnings you should know about:**Use in Children**

Young children are at greater risk of the sedating effects of narcotic cough drugs. COPHYLAC[®] should be given with caution to children. This is especially true for children who have difficulty breathing. COPHYLAC[®] is not recommended for children under 6.

Opioid dependence and addiction: There are important differences between physical dependence and addiction. It is important that you talk to your doctor if you have questions or concerns about abuse, addiction or physical dependence.

Pregnancy, nursing, labour and delivery:

Do not use COPHYLAC[®] while pregnant, nursing, during labour or delivery. Opioids can be transferred to your baby through breast milk, or while still in the womb. COPHYLAC[®] can then cause life-threatening breathing problems in your unborn baby or nursing infant.

If you are pregnant and are taking COPHYLAC[®], it is important that you don't stop taking your medication all of a sudden. If you do, it can cause a miscarriage or a still-birth. Your doctor will monitor and guide you on how to slowly stop taking COPHYLAC[®]. This may help avoid serious harm to your unborn baby.

Driving and using machines: Before you do tasks which may require special attention, you should wait until you know how you react to COPHYLAC[®]. COPHYLAC[®] can cause:

- drowsiness
- dizziness or
- lightheadedness

This can usually occur after you take your first dose and when your dose is increased.

Disorder of the adrenal gland: You may develop a disorder of the adrenal gland called adrenal insufficiency. This means that your adrenal gland is not making enough of certain hormones. You may experience symptoms such as:

- nausea, vomiting
- feeling tired, weak or dizzy
- decreased appetite

You may be more likely to have problems with your adrenal gland if you have been taking opioids for longer than one month. Your doctor may do tests, give you another medication, and slowly take you off COPHYLAC[®].

Serotonin Syndrome: Opioids can cause Serotonin Syndrome, a rare but potentially life-threatening condition. It can cause serious changes in how your brain, muscles and digestive system work. You may develop Serotonin Syndrome if you take COPHYLAC[®] with certain anti-depressants or migraine medications.

Serotonin Syndrome symptoms include:

- fever, sweating, shivering, diarrhea, nausea, vomiting;
- muscle shakes, jerks, twitches or stiffness, overactive reflexes, loss of coordination;
- fast heartbeat, changes in blood pressure;
- confusion, agitation, restlessness, hallucinations, mood changes, unconsciousness, and coma.

Sexual Function/Reproduction: Long term use of opioids may lead to a decrease in sex hormone levels. It may also lead to low libido (desire to have sex), erectile dysfunction or being infertile.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with COPHYLAC®:

- Alcohol. This includes prescription and non-prescription medications that contain alcohol. **Do not** drink alcohol while you are taking COPHYLAC®. It can lead to:
 - drowsiness
 - unusually slow or weak breathing
 - serious side effects or
 - a fatal overdose
- other sedative drugs which may enhance the drowsiness caused by COPHYLAC®
- opioid analgesics (drugs used to treat pain)
- general anesthetics (drugs used during surgery)
- benzodiazepines (drugs used to help you sleep or that help reduce anxiety)
- antidepressants (for depression and mood disorders). **Do not** take COPHYLAC® with MAO inhibitors (MAOi) or if you have taken MAOi's in the last 14 days.
- drugs used to treat serious mental or emotional disorders (such as schizophrenia)
- antihistamines (drugs used to treat allergies)
- anti-emetics (drugs used to prevent vomiting)
- drugs used to treat muscle spasms and back pain
- some heart medications (such as beta blockers)
- drugs used to treat migraines (e.g. triptans)
- St. John's Wort

How to take COPHYLAC®:

COPHYLAC® may be taken plain with sugar or in any beverage, preferably after breakfast and at bedtime.

Usual Dose:

Be sure to follow your doctor's dosing instructions exactly. Do not increase or decrease your dose without consulting your doctor.

Your doctor will prescribe the lowest dose that works to control your cough. Higher doses can lead to more side effects and a greater chance of overdose. Review your symptoms regularly with your doctor to determine if you still need COPHYLAC®. Be sure to use COPHYLAC® only for the condition for which it was prescribed.

If you develop any side effect as a result of taking COPHYLAC®, tell your doctor immediately.

Adults and children over 14 years: The recommended dosage is 15 drops twice daily.

Children between 6 to 14 years of age: The recommended dosage is 5 to 10 drops twice daily.

Stopping your Medication

If you have been taking COPHYLAC[®] for more than a few days you may experience some of the following uncomfortable symptoms when you stop taking it:

- body aches
- diarrhea
- goosebumps
- loss of appetite
- nausea
- feeling nervous or restless
- runny nose
- sneezing
- tremors or shivering
- stomach cramps
- rapid heart rate (tachycardia)
- having trouble sleeping
- an unusual increase in sweating
- heart palpitations
- an unexplained fever
- weakness
- yawning

Refilling your Prescription for COPHYLAC[®]:

A new written prescription is required from your doctor each time you need more COPHYLAC[®]. Only obtain prescriptions for this medicine from the doctor in charge of your treatment. Do not seek prescriptions from other doctors unless you switch to another doctor.

Overdose:

If you think you have taken too much COPHYLAC [®] , contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.
--

Signs of overdose may include:

- unusually slow or weak breathing
- dizziness
- confusion
- extreme drowsiness

Missed Dose:

If you missed a dose of this medication, take it as soon as you remember. But if it is almost time for your next dose, skip the missed dose and continue with your next scheduled dose. Go back to the regular dosing schedule. Do not take two doses at the same time. If you miss several doses in a row, talk to your doctor before restarting your medication.

What are possible side effects from using COPHYLAC®?

These are not all the possible side effects you may feel when taking COPHYLAC®. If you experience any side effects not listed here, contact your healthcare professional.

Side effects may include:

- Drowsiness
- Insomnia
- Dizziness
- Fainting
- Nausea, vomiting, or a poor appetite
- Dry mouth
- Headache
- Problems with vision
- Weakness, uncoordinated muscle movement
- Itching
- Light headedness
- Sweating
- Constipation
- Low sex drive, impotence (erectile dysfunction), infertility

Talk with your doctor or pharmacist about ways to prevent constipation when you start using COPHYLAC®

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
RARE Overdose: hallucinations, confusion, inability to walk normally, slow or weak breathing, extreme sleepiness, sedation, or dizziness, floppy muscles/low muscle tone cold and clammy skin.			✓
Respiratory Depression: Slow, shallow or weak breathing.			✓
Allergic Reaction: rash, hives, swelling of the face, lips, tongue or throat, difficulty swallowing or breathing			✓
Bowel Blockage (impaction): abdominal pain, severe constipation, nausea			✓
Withdrawal: nausea, vomiting, diarrhea, anxiety, shivering, cold and clammy skin, body aches, loss of appetite, sweating.		✓	
Fast, Slow or Irregular Heartbeat: heart		✓	

palpitations.			
Low Blood Pressure: dizziness, fainting, light-headedness.	✓		
Serotonin Syndrome: agitation or restlessness, loss of muscle control or muscle twitching, tremor, diarrhea			✓

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects

We encourage you to report serious or unexpected side effects to Health Canada. The information is used to check for new safety concerns about health products. As a consumer, your report contributes to the safe use of health products for everyone.

3 ways to report:

- Online at **MedEffect**: <https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>
- By calling 1-866-234-2345 (toll-free);
- By completing a Consumer Side Effect Reporting Form and sending it by:
 - Fax to 1-866-678-6789 (toll-free), or
 - Mail to: Canada Vigilance Program
Health Canada, Postal Locator 1908C
Ottawa, ON
K1A 0K9

Postage paid labels and the Consumer Side Effect Reporting Form are available at **MedEffect**. (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>).

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

Storage:

- **COPHYLAC[®] should be stored at room temperature between 15 °C and 30 °C.**
- **Keep unused or expired COPHYLAC[®] in a secure place to prevent theft, misuse or accidental exposure to children and pets.**
- **Keep COPHYLAC[®] out of sight and reach of children and pets.**
- **Never take medicine in front of small children as they will want to copy you. Accidental ingestion by a child is dangerous and may result in death. If a child accidentally takes COPHYLAC[®], get emergency help right away.**

Disposal:

COPHYLAC[®] should never be thrown into household trash, where children and pets may find it. It should be returned to a pharmacy for proper disposal.

If you want more information about COPHYLAC[®]:

- Talk to your healthcare professional

- Find the full product monograph that is prepared for healthcare professionals and includes this consumer medication information by visiting the [Health Canada website;](https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html) (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>) or by calling 1-800-361-4261.

This leaflet was prepared by Valeant Canada LP.
Last revised: May 30, 2018